baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GSK plc/ US37733W2044 /

03/06/2024 22:10:00	Chg. -3.89	Volume	Bid10:59:10	Ask10:59:10	High	Low
40.88USD	-8.69%	13.48 mill. Turnover: 401.35 mill.	40.85Bid Size: 1,300	40.88Ask Size: 1,100	41.72	40.51

GlobeNewswire 07:00 BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

GlobeNewswire 03/06 Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TeleTrader 03/06 Europe closes mostly higher after PMI data

TeleTrader 03/06 GSK plunges 10% after Zantac ruling

GlobeNewswire 30/05 SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth

GlobeNewswire 28/05 Actuate Therapeutics Files Registration Statement for Initial Public Offering

GlobeNewswire 28/05 Recommendation from Equinor's nomination committee

GlobeNewswire 23/05 Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant impr...

GlobeNewswire 23/05 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

GlobeNewswire 21/05 Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP...

GlobeNewswire 16/05 Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

GlobeNewswire 15/05 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 10/05 iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 10/05 iTeos Therapeutics Announces $120 Million Registered Direct Offering

GlobeNewswire 09/05 Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 09/05 Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...

GlobeNewswire 09/05 Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...

GlobeNewswire 09/05 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 09/05 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

GlobeNewswire 09/05 Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

GlobeNewswire 08/05 SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 08/05 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08/05 Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...

GlobeNewswire 08/05 Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...

GSK plc/ US37733W2044 /

If you wish to receive reply to your feedback, please provide your email address.